Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo - PubMed (original) (raw)

Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo

D P Sharma et al. J Virol. 1996 Oct.

Abstract

Interleukin-4 (IL-4) promotes the growth of Th2-type cells while down regulating the development of Th1-type cells. It has been suggested that the actions of this factor inhibit Th1-type effector activity in vivo and may underlie the development of diseases normally controlled by cell-mediated immune responses. Here, we show that clearance of recombinant vaccinia viruses (VV) engineered to express the gene for murine IL-4 is markedly delayed in mice compared with control recombinant VV. While antiviral antibody levels and NK activity in mice given control virus or IL-4-expressing virus were similar, antiviral cytotoxic T-lymphocyte responses were profoundly suppressed throughout the course of infection with the latter. Limiting dilution analysis of IL-4-virus-infected spleens revealed a marked reduction in numbers of cytotoxic T-lymphocyte precursors. Furthermore, reverse transcriptase PCR analysis of splenic mRNA prepared from mice infected with the IL-4-expressing VV showed a marked down regulation of IL-12, gamma interferon, and IL-2 gene expression compared with that from mice given control virus. IL-4 also inhibited the production of nitric oxide (NO), a potent mediator of antimicrobial activity. Together, these data show that IL-4 markedly suppresses the development of antiviral cell-mediated immune responses in vivo with deleterious effects on virus clearance.

PubMed Disclaimer

Cited by

Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses.
Freyschmidt EJ, Mathias CB, Diaz N, MacArthur DH, Laouar A, Manjunath N, Hofer MD, Wurbel MA, Campbell JJ, Chatila TA, Oettgen HC. Freyschmidt EJ, et al. J Immunol. 2010 Jul 15;185(2):1295-302. doi: 10.4049/jimmunol.0903144. Epub 2010 Jun 14. J Immunol. 2010. PMID: 20548030 Free PMC article.
Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response.
Oyoshi MK, Elkhal A, Kumar L, Scott JE, Koduru S, He R, Leung DY, Howell MD, Oettgen HC, Murphy GF, Geha RS. Oyoshi MK, et al. Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14954-9. doi: 10.1073/pnas.0904021106. Epub 2009 Aug 17. Proc Natl Acad Sci U S A. 2009. PMID: 19706451 Free PMC article.
Emodin as an Inhibitor of PRV Infection In Vitro and In Vivo.
Cai X, Wang Z, Li X, Zhang J, Ren Z, Shao Y, Xu Y, Zhu Y. Cai X, et al. Molecules. 2023 Sep 11;28(18):6567. doi: 10.3390/molecules28186567. Molecules. 2023. PMID: 37764342 Free PMC article.
Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.
Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Kent SJ, et al. J Virol. 1998 Dec;72(12):10180-8. doi: 10.1128/JVI.72.12.10180-10188.1998. J Virol. 1998. PMID: 9811759 Free PMC article.
Immune response against toxoplasmosis-some recent updates RH: Toxoplasma gondii immune response.
Sana M, Rashid M, Rashid I, Akbar H, Gomez-Marin JE, Dimier-Poisson I. Sana M, et al. Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221078436. doi: 10.1177/03946320221078436. Int J Immunopathol Pharmacol. 2022. PMID: 35227108 Free PMC article. Review.

References

1. Annu Rev Immunol. 1994;12:635-73 - PubMed
1. Science. 1994 Apr 22;264(5158):561-3 - PubMed
1. J Exp Med. 1994 Nov 1;180(5):1715-28 - PubMed
1. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12659-63 - PubMed
1. J Virol. 1995 Mar;69(3):1955-8 - PubMed

Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo - PubMed (original) (raw)